МЕТАБОЛІЧНІ ІНГІБІТОРИ ТА ЇХ ВПЛИВ НА МІГРАЦІЮ, ІНВАЗІЮ ТА МЕТАСТАЗУВАННЯ РАКОВИХ КЛІТИН
DOI:
https://doi.org/10.15407/exp-oncology.2026.01.011Ключові слова:
інгібітори гліколізу, інгібітори окисного фосфорилювання, міграція, інвазія, метастазуванняАнотація
Метастазування — процес, за допомогою якого ракові клітини поширюються з первинної пухлини у віддалені ділянки, залишається основною причиною смерті онкологічних хворих. Цей процес включає відшарування клітин, міграцію, інвазію, виживання в системі кровообігу, екстравазацію та колонізацію нових тканин. Фун- даментальною характеристикою ракових клітин є їхній змінений метаболізм, який часто демонструє підви- щене споживання глюкози та перевагу гліколізу навіть за наявності кисню, явище, відоме як ефект Варбурга. Цей метаболічний зсув забезпечує ракові клітини швидким джерелом аденозинтрифосфату та необхідних біосинтетичних проміжних продуктів, що підтримує їхній швидкий ріст та проліферацію. Хоча ранні теорії вважали дефект мітохондріального окисного фосфорилювання причиною ефекту Варбурга, зараз визнано, що мітохондрії в ракових клітинах часто функціональні та відіграють вирішальну роль у різних клітинних процесах. Примітно, що метастатичні клітини часто демонструють залежність від мітохондріального дихання та окисного фосфорилювання, що свідчить про потенційну метаболічну адаптацію, яка стимулює прогресу- вання раку. Цей огляд розглядає механізми, за допомогою яких інгібітори гліколізу та окисного фосфорилю- вання впливають на міграцію, інвазію та метастазування пухлинних клітин, а також висвітлює перспективи їх терапевтичного застосування.
Посилання
Feng Y, Xiong Y, Qiao T, et al. Lactate dehydrogenase A: A key player in carcinogenesis and potential target in cancer therapy. Cancer Med. 2018;7(12):6124-6136. https://doi.org/10.1002/cam4.1820
Erdem A, Kaye S, Caligiore F, et al. Lactate dehydrogenase A-coupled NAD+ regeneration is critical for acute myeloid leukemia cell survival. Cancer Metab. 2025;13(1):22. https://doi.org/10.1186/s40170-025-00392-4
Zhao Z, Han F, Yang S, et al. Oxamate-mediated inhibition of lactate dehydrogenase induces protective autophagy in gastric cancer cells: involvement of the Akt-mTOR signaling pathway. Cancer Lett. 2015;358(1):17-26. https://doi.org/10.1016/j.canlet.2014.11.046
Al-Salam S, Kandhan K, Sudhadevi M. Down regulation of lactate dehydrogenase initiates apoptosis in HeLa and MCF-7 cancer cells through increased voltage-dependent anion channel protein and inhibition of BCL2. Oncotarget. 2021;12(9):923-935. https://doi.org/10.18632/oncotarget.27950
Zhai X, Yang Y, Wan J, et al. Inhibition of LDH-A by oxamate induces G2/M arrest, apoptosis and increases radiosensitivity in nasopharyngeal carcinoma cells. Oncol Rep. 2013;30(6):2983-2991. https://doi.org/10.3892/or.2013.2735
Calibasi-Kocal G, Cakici C, Toksoz F, et al. Targeting the tumor metabolism by oxamate potentiates the impact of chemotherapeutics in colorectal cancer cells. J Basic Clin Health Sci. 2021;5(3):205-212. https://doi.org/10.30621/jbachs.988996
Forkasiewicz A, Stach W, Wierzbicki J, et al. Effect of LDhA inhibition on TNF-α-induced cell migration in esophageal cancers. Int J Mol Sci. 2022;23(24):16062. https://doi.org/10.3390/ijms232416062
Liu X, Yang Z, Chen Z, et al. Effects of the suppression of lactate dehydrogenase A on the growth and invasion of human gastric cancer cells. Oncol Rep. 2015;33(1):157-162. https://doi.org/10.3892/or.2014.3600
Stepanov Y, Kolesnik D, Yakshibaeva Y, et al. Effect of adhesive LLC cell pretreatment by oxamate on the survival indexes after transition to de-adhesive growth. Exp Oncol. 2024;46(3):237-243. https://doi.org/10.15407/exp-oncology.2024.03.237
Bai R, Meng Y, Cui J. Therapeutic strategies targeting metabolic characteristics of cancer cells. Crit Rev Oncol Hematol. 2023;187:104037. https://doi.org/10.1016/j.critrevonc.2023.104037
Yang Y, Su D, Zhao L, et al. Different effects of LDH-A inhibition by oxamate in non-small cell lung cancer cells. Oncotarget. 2014;5(23):11886-11896. https://doi.org/10.18632/oncotarget.2620
Dwarakanath B, Jain V. Targeting glucose metabolism with 2-deoxy-D-glucose for improving cancer therapy. Future Oncol. 2009;5(5):581-585. https://doi.org/10.2217/fon.09.44
Fujita M, Imadome K, Somasundaram V, et al. Metabolic characterization of aggressive breast cancer cells exhibiting invasive phenotype: impact of non-cytotoxic doses of 2-DG on diminishing invasiveness. BMC Cancer. 2020;20(1):929. https://doi.org/10.1186/s12885-020-07414-y
O’Neill S, Porter RK, McNamee N, et al. 2-Deoxy-D-Glucose inhibits aggressive triple-negative breast cancer cells by targeting glycolysis and the cancer stem cell phenotype. Sci Rep. 2019;9(1):3788. https://doi.org/10.1038/s41598-019-39789-9
Zhong D, Xiong L, Liu T, et al. The glycolytic inhibitor 2-deoxyglucose activates multiple prosurvival pathways through IGF1R. J Biol Chem. 2009;284(35):23225-23233. https://doi.org/10.1074/jbc.M109.005280
Zhang D, Fei Q, Li J, et al. 2-Deoxyglucose reverses the promoting effect of insulin on colorectal cancer cells in vitro. PLoS One. 2016;11(3):e0151115. https://doi.org/10.1371/journal.pone.0151115
Vorobyev PO, Kochetkov DV, Chumakov PM, et al. 2-Deoxyglucose, an inhibitor of glycolysis, enhances the oncolytic effect of coxsackievirus. Cancers (Basel). 2022;14(22):5611. https://doi.org/10.3390/cancers14225611
Sasawatari S, Okamoto Y, Kumanogoh A, et al. Blockade of N-glycosylation promotes antitumor immune response of T cells. J Immunol. 2020;204(5):1373-1385. https://doi.org/10.4049/jimmunol.1900937
Minor RK, Smith DL Jr, Sossong AM, et al. Chronic ingestion of 2-deoxy-D-glucose induces cardiac vacuolization and increases mortality in rats. Toxicol Appl Pharmacol. 2010;243(3):332-339. https://doi.org/10.1016/j.taap.2009.11.025
Shin S, Yang S, Kim M, et al. Fatty acid oxidation supports melanoma cell migration through autophagy regulation. Biochem Biophys Res Commun. 2023;674:124-132. https://doi.org/10.1016/j.bbrc.2023.06.090
De Oliveira MP, Liesa M. The role of mitochondrial fat oxidation in cancer cell proliferation and survival. Cells. 2020;9(12):2600. https://doi.org/10.3390/cells9122600
Sottnik JL, Lori JC, Rose BJ, et al. Glycolysis inhibition by 2-deoxy-D-glucose reverts the metastatic phenotype in vitro and in vivo. Clin Exp Metastasis. 2011;28(8):865-875. https://doi.org/10.1007/s10585-011-9417-5
Baghdadi HH. Targeting cancer cells using 3-bromopyruvate for selective cancer treatment. Saudi J Med Med Sci. 2017;5(1):9-19. https://doi.org/10.4103/1658-631X.194253
Jardim-Messeder D, Moreira-Pacheco F. 3-Bromopyruvic acid inhibits tricarboxylic acid cycle and glutaminolysis in HepG2 cells. Anticancer Res. 2016;36(5):2233-2241. PMID: 27127128
Azevedo-Silva J, Tavares-Valente D, Almeida A, et al. Cytoskeleton disruption by the metabolic inhibitor 3-bromopyruvate: Implications in cancer therapy. Med Oncol. 2022;39(9):121. https://doi.org/10.1007/s12032-022-01712-0
Fan T, Sun G, Sun X, et al. Tumor energy metabolism and potential of 3-bromopyruvate as an inhibitor of aerobic glycolysis: Implications in tumor treatment. Cancers (Basel). 2019;11(3):317. https://doi.org/10.3390/cancers11030317
Pan Q, Sun Y, Jin Q, et al. Hepatotoxicity and nephrotoxicity of 3-bromopyruvate in mice. Acta Cir Bras. 2016;31(11):724-729. https://doi.org/10.1590/S0102-865020160110000004
Shoshan MC. 3-Bromopyruvate: targets and outcomes. J Bioenerg Biomembr. 2012;44(1):7-15. https://doi.org/10.1007/s10863-012-9419-2
Cardaci S, Rizza S, Filomeni G, et al. Glutamine deprivation enhances antitumor activity of 3-bromopyruvate through the stabilization of monocarboxylate transporter-1. Cancer Res. 2012;72(17):4526-4536. https://doi.org/10.1158/0008-5472.CAN-12-1741
Yang K, Wang X, Song C, et al. The role of lipid metabolic reprogramming in tumor microenvironment. Theranostics. 2023;13(6):1774-1808. https://doi.org/10.7150/thno.82920
Desbats MA, Giacomini I, Prayer-Galetti T, et al. Metabolic plasticity in chemotherapy resistance. Front Oncol. 2020;10:281. https://doi.org/10.3389/fonc.2020.00281
Jiang Z, He J, Zhang B, et al. A potential «anti-warburg effect» in circulating tumor cell-mediated metastatic progression? Aging Dis. 2024;16(1):269-282. https://doi.org/10.14336/AD.2023.1227
Nancolas B, Guo L, Zhou R, et al. The anti-tumour agent lonidamine is a potent inhibitor of the mitochondrial pyruvate carrier and plasma membrane monocarboxylate transporters. Biochem J. 2016;473(7):929-936. https://doi.org/10.1042/BJ20151120
Huang Y, Sun G, Sun X, et al. The potential of lonidamine in combination with chemotherapy and physical therapy in cancer treatment. Cancers (Basel). 2020;12(11):3332. https://doi.org/10.3390/cancers12113332
Iqbal MA, Bamezai RN. Resveratrol inhibits cancer cell metabolism by down regulating pyruvate kinase M2 via inhibition of mammalian target of rapamycin. PLoS One. 2012;7(5):e36764. https://doi.org/10.1371/journal.pone.0036764
Zheng X, Pan Y, Yang G, et al. Kaempferol impairs aerobic glycolysis against melanoma metastasis via inhibiting the mitochondrial binding of HK2 and VDAC1. Eur J Pharmacol. 2022;931:175226. https://doi.org/10.1016/j.ejphar.2022.175226
Pan Y, Zheng Q, Ni W, et al. Breaking glucose transporter 1/pyruvate kinase M2 glycolytic loop is required for cantharidin inhibition of metastasis in highly metastatic breast cancer. Front Pharmacol. 2019;10:590. https://doi.org/10.3389/fphar.2019.00590
Yang T, Zhang X, Yang X, et al. A mitochondria-targeting self-assembled carrier-free lonidamine nanodrug for redox-activated drug release to enhance cancer chemotherapy. J Mater Chem B. 2023;11(17):3951-3957. https://doi.org/10.1039/d2tb02728c
Bhutia YD, Babu E, Ganapathy V. Re-programming tumour cell metabolism to treat cancer: No lone target for lonidamine. Biochem J. 2016;473(11):1503-1506. https://doi.org/10.1042/BCJ20160068
Aggarwal V, Tuli HS, Varol A, et al. Role of reactive oxygen species in cancer progression: Molecular mechanisms and recent advancements. Biomolecules. 2019;9(11):735. https://doi.org/10.3390/biom9110735
Ko JH, Sethi G, Um JY, et al. The role of resveratrol in cancer therapy. Int J Mol Sci. 2017;18(12):2589. https://doi.org/10.3390/ijms18122589
Berman AY, Motechin RA, Wiesenfeld MY, et al. The therapeutic potential of resveratrol: A review of clinical trials. NPJ Precis Oncol. 2017;1:35. https://doi.org/10.1038/s41698-017-0038-6
Carter LG, D’Orazio JA, Pearson KJ. Resveratrol and cancer: focus on in vivo evidence. Endocr Relat Cancer. 2014;21(3):209-225. https://doi.org/10.1530/ERC-13-0171
Shaito A, Posadino AM, Younes N, et al. Potential adverse effects of resveratrol: A literature review. Int J Mol Sci. 2020;21(6):2084. https://doi.org/10.3390/ijms21062084
Pujalte-Martin M, Belaïd A, Bost S, et al. Targeting cancer and immune cell metabolism with the complex I inhibitors metformin and IACS-010759. Mol Oncol. 2024;18(7):1719-1738. https://doi.org/10.1002/1878-0261.13583
Kalyanaraman B, Cheng G, Hardy M, et al. OXPHOS-targeting drugs in oncology: New perspectives. Expert Opin Ther Targets. 2023;27(10):939-952. https://doi.org/10.1080/14728222.2023.2261631
Andrzejewski S, Siegel PM, St-Pierre J. Metabolic profiles associated with metformin efficacy in cancer. Front Endocrinol (Lausanne). 2018;9:372. https://doi.org/10.3389/fendo.2018.00372
Chen YC, Li H, Wang J. Mechanisms of metformin inhibiting cancer invasion and migration. Am J Transl Res. 2020;12(9):4885-4901. PMID: 33042396
Denisenko TV, Gorbunova AS, Zhivotovsky B. Mitochondrial involvement in migration, invasion and metastasis. Front Cell Dev Biol. 2019;7:355. https://doi.org/10.3389/fcell.2019.00355
Chen N, Zhou YS, Wang LC, et al. Advances in metformin-based metabolic therapy for non-small cell lung cancer (Review). Oncol Rep. 2022;47(3):55. https://doi.org/10.3892/or.2022.8266
Arner EN, Jennings EQ, Crooks DR, et al. Impaired oxidative phosphorylation drives primary tumor escape and metastasis. bioRxiv [Preprint]. 2025:2025.01.08.631936. https://doi.org/10.1101/2025.01.08.631936
Han SY, Jeong YJ, Choi Y, et al. Mitochondrial dysfunction induces the invasive phenotype, and cell migration and invasion, through the induction of Akt and AMPK pathways in lung cancer cells. Int J Mol Med. 2018;42(3):1644-1652. https://doi.org/10.3892/ijmm.2018.3733
Caino MC, Altieri DC. Molecular pathways: Mitochondrial reprogramming in tumor progression and therapy. Clin Cancer Res. 2016;22(3):540-545. https://doi.org/10.1158/1078-0432.CCR-15-0460
Mehmood T, Nasir Q, Younis I, et al. Inhibition of mitochondrial dynamics by mitochondrial division inhibitor-1 suppresses cell migration and metastatic markers in colorectal cancer HCT116 cells. J Exp Pharmacol. 2025;17:143-157. https://doi.org/10.2147/JEP.S510578
Yap TA, Daver N, Mahendra M, et al. Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: Phase I trials. Nat Med. 2023;29(1):115-126. https://doi.org/10.1038/s41591-022-02103-8
Tello D, Balsa E, Acosta-Iborra B, et al. Induction of the mitochondrial NDUFA4L2 protein by HIF-1α decreases oxygen consumption by inhibiting Complex I activity. Cell Metab. 2011;14(6):768-779. https://doi.org/10.1016/j.cmet.2011.10.008
Zielonka J, Joseph J, Sikora A, et al. Mitochondria-targeted triphenylphosphonium-based compounds: Syntheses, mechanisms of action, and therapeutic and diagnostic applications. Chem Rev. 2017;117(15):10043-10120. https://doi.org/10.1021/acs.chemrev.7b00042
Lhuissier C, Desquiret-Dumas V, Girona A, et al. Mitochondrial F0F1-ATP synthase governs the induction of mitochondrial fission. iScience. 2024;27(5):109808. https://doi.org/10.1016/j.isci.2024.109808
Hytti M, Korhonen E, Hyttinen JMT, et al. Antimycin A-induced mitochondrial damage causes human RPE cell death despite activation of autophagy. Oxid Med Cell Longev. 2019;2019:1583656. https://doi.org/10.1155/2019/1583656
Bordt EA, Clerc P, Roelofs BA, et al. The putative Drp1 inhibitor mdivi-1 is a reversible mitochondrial complex I inhibitor that modulates reactive oxygen species. Dev Cell. 2017;40(6):583-594. https://doi.org/10.1016/j.devcel.2017.02.020
Pavlovic K, Krako Jakovljevic N, Isakovic AM, et al. Therapeutic vs. suprapharmacological metformin concentrations: different effects on energy metabolism and mitochondrial function in skeletal muscle cells in vitro. Front Pharmacol. 2022;13:930308. https://doi.org/10.3389/fphar.2022.930308
Choi YK, Park KG. Metabolic roles of AMPK and metformin in cancer cells. Mol Cells. 2013;36(4):279-287. https://doi.org/10.1007/s10059-013-0169-8
Shuvalov O, Daks A, Fedorova O, et al. Linking metabolic reprogramming, plasticity and tumor progression. Cancers (Basel). 2021;13(4):762. https://doi.org/10.3390/cancers13040762
Jia D, Lu M, Jung KH, et al. Elucidating cancer metabolic plasticity by coupling gene regulation with metabolic pathways. Proc Natl Acad Sci U S A. 2019;116(9):3909-3918. https://doi.org/10.1073/pnas.1816391116
Hua Y, Zheng Y, Yao Y, et al. Metformin and cancer hallmarks: Shedding new lights on therapeutic repurposing. J Transl Med. 2023;21(1):403. https://doi.org/10.1186/s12967-023-04263-8
Jiang J, Wang K, Chen Y, et al. Redox regulation in tumor cell epithelial-mesenchymal transition: Molecular basis and therapeutic strategy. Signal Transduct Target Ther. 2017;2:17036. https://doi.org/10.1038/sigtrans.2017.36
Taha M, Azhary A, Hajhamed NM, et al. A case report of metformin-associated lactic acidosis. Clin Case Rep. 2024;12(8):e9255. https://doi.org/10.1002/ccr3.9255
Buczyńska A, Sidorkiewicz I, Krętowski AJ, et al. Metformin intervention—A panacea for cancer treatment? Cancers (Basel). 2022;14(5):1336. https://doi.org/10.3390/cancers14051336
Zheng J. Energy metabolism of cancer: Glycolysis versus oxidative phosphorylation (Review). Oncol Lett. 2012;4(6):1151-1157. https://doi.org/10.3892/ol.2012.928
Aisu Y, Oshima N, Hyodo F, et al. Dual inhibition of oxidative phosphorylation and glycolysis exerts a synergistic antitumor effect on colorectal and gastric cancer by creating energy depletion and preventing metabolic switch. PLoS One. 2024;19(12):e0309700. https://doi.org/10.1371/journal.pone.0309700
Chen D, Barsoumian HB, Fischer G, et al. Combination treatment with radiotherapy and a novel oxidative phosphorylation inhibitor overcomes PD-1 resistance and enhances antitumor immunity. J Immunother Cancer. 2020;8(1):e000289. https://doi.org/10.1136/jitc-2019-000289
Yu L, Lu M, Jia D, et al. Modeling the genetic regulation of cancer metabolism: Interplay between glycolysis and oxidative phosphorylation. Cancer Res. 2017;77(7):1564-1574. https://doi.org/10.1158/0008-5472.CAN-16-2074
Luo Z, Eichinger KM, Zhang A, et al. Targeting cancer metabolic pathways for improving chemotherapy and immunotherapy. Cancer Lett. 2023;575:216396. https://doi.org/10.1016/j.canlet.2023.216396
Chelakkot C, Chelakkot VS, Shin Y, et al. Modulating glycolysis to improve cancer therapy. Int J Mol Sci. 2023;24(3):2606. https://doi.org/10.3390/ijms24032606
Dwarakanath BS, Singh D, Banerji AK, et al. Clinical studies for improving radiotherapy with 2-deoxy-D-glucose: present status and future prospects. J Cancer Res Ther. 2009;5(Suppl 1):S21-S26. https://doi.org/10.4103/0973-1482.55136
Hashimoto T, Ushikubo G, Arao N, et al. Oxamate, an LDhA inhibitor, inhibits stemness, including EMT and high DNA repair ability, induces senescence, and exhibits radiosensitizing effects in glioblastoma cells. Int J Mol Sci. 2025;26(12):5710. https://doi.org/10.3390/ijms26125710
Yang Y, Chong Y, Chen M, et al. Targeting lactate dehydrogenase A improves radiotherapy efficacy in non-small cell lung cancer: from bedside to bench. J Transl Med. 2021;19(1):170. https://doi.org/10.1186/s12967-021-02825-2
Altinoz MA, Ozpinar A. Oxamate targeting aggressive cancers with special emphasis to brain tumors. Biomed Pharmacother. 2022;147:112686. https://doi.org/10.1016/j.biopha.2022.112686
Verma S, Budhu S, Serganova I, et al. Pharmacologic LDH inhibition redirects intratumoral glucose uptake and improves antitumor immunity in solid tumor models. J Clin Invest. 2024;134(17):e177606. https://doi.org/10.1172/JCI177606
Stepanov YV, Yakshibaeva YR, Kolesnik DL, et al. 2-Deoxyglucose promotes anti-inflammatory polarization of peritoneal macrophages in mice with Lewis lung carcinoma. Oncology. 2024;26(1):44-48 (in Ukrainian). https://doi.org/10.15407/oncology.2024.01.044
Tang C, Tang X, Tang J, et al. An oxygen-generating nanoplatform remodels the immunosuppressive tumor microenvironment via synergistic lactate depletion and sonodynamic therapy. J Nanobiotechnology. 2025;23(1):458. https://doi.org/10.1186/s12951-025-03524-6
##submission.downloads##
Опубліковано
Як цитувати
Номер
Розділ
Ліцензія
Авторське право (c) 2026 Експериментальна онкологія
Ця робота ліцензується відповідно до Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
